Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 2863-2873

  Chiong, Edmund ^a   Lee, I Ling ^b   Dadbin, Ali ^b   Sabichi, Anita L ^b   Harris, Loleta ^b   Urbauer, Diana ^b   McConkey, David J ^b   Dickstein, Rian J ^b   Cheng, Tiewei ^b   Grossman, H Barton ^b  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL FRACTIONATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, TRANSITIONAL CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MICE; MICE, NUDE; PROTEIN BIOSYNTHESIS; SIROLIMUS; TOR SERINE-THREONINE KINASES; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79955505851     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3202     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA: Cancer J Clin 2007;57:43-66.
2. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62-7. (Pubitemid 27251595)
3. Herr HW. Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol 1997;15:84-8. (Pubitemid 127763990)
4. Black PC, Brown GA, Grossman HB, Dinney CP. Neoadjuvant chemotherapy for bladder cancer. World J Urol 2006;24:531-42. (Pubitemid 44782307)
5. Warde P, Gospodarowicz MK. New approaches in the use of radiation therapy in the treatment of infiltrative transitional-cell cancer of the bladder. World J Urol 1997;15:125-33. (Pubitemid 127763997)
6. Corral DA, Logothetis CJ. New approaches in the treatment of metastatic transitional-cell cancer of the bladder. World J Urol 1997;15:139-43. (Pubitemid 127763999)
7. Dancey JE. Therapeutic targets: MTOR and related pathways. Cancer Biol Ther 2006;5:1065-73. (Pubitemid 44773684)
8. Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ 2002;9:99-100. (Pubitemid 34144768)
9. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene 2006;25:6416-22. (Pubitemid 44582285)
10. Wu X, Obata T, Khan Q, Highshaw RA, De Vere White R, Sweeney C. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 2004;93:143-50. (Pubitemid 38112985)
11. Tanaka M, Koul D, Davies MA, Liebert M, Steck PA, Grossman HB. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 2000;19:5406-12.
12. Alessi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 1998;8:55-62. (Pubitemid 28122141)
13. Sandberg AA, Berger CS. Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J Urol 1994;151:545-60. (Pubitemid 24054683)
14. Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene 1997;14:3059-66. (Pubitemid 27336321)
15. Cairns P, Evron E, Okami K, Halachmi N, Esteller M, Herman JG, et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 1998;16:3215-8. (Pubitemid 28318794)
16. Aveyard JS, Skilleter A, Habuchi T, Knowles MA. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999;80:904-8. (Pubitemid 29209858)
17. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 2009;23:675-80.
18. Fechner G, Classen K, Schmidt D, Hauser S, Muller SC. Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. Urology 2009;73:665-8; discussion 668-9.
19. Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, Kassouf W. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther 2009;8:2339-47.
20. Chiong E, Dadbin A, Harris LD, Sabichi AL, Grossman HB. The use of short tandem repeat profiling to characterize human bladder cancer cell lines. J Urol 2009;181:2737-48.
21. Kanamaru H, Yoshida O. Assessment of in vitro lymphokine activated killer (LAK) cell activity against renal cancer cell lines and its suppression by serum factor using crystal violet assay. Urol Res 1989;17:259-64. (Pubitemid 19187289)
22. Poole B, Wibo M. Protein degradation in cultured cells. The effect of fresh medium, fluoride, and iodoacetate on the digestion of cellular protein of rat fibroblasts. J Biol Chem 1973;248:6221-6.
23. Sasaki T, Nakamura T, Rebhun RB, Cheng H, Hale KS, Tsan RZ, et al. Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model. Am J Pathol 2008;173:205-16. (Pubitemid 351947968)
24. Laplanche R, Meno-Tetang GM, Kawai R. Physiologically based pharmacokinetic (PBPK) modeling of everolimus (RAD001) in rats involving non-linear tissue uptake. J Pharmacokin Pharmacodyn 2007;34:373-400. (Pubitemid 46873032)
25. Tanaka M, Grossman HB. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Ther 2003;10:1636-42.
26. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009;27:2278-87.
27. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-68.
28. Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001;8:249-58. (Pubitemid 32947647)
29. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, et al. Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26:1603-10.
30. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-45. (Pubitemid 39071573)
31. Lehman N, Ledford B, Di Fulvio M, Frondorf K, McPhail LC, Gomez-Cambronero J. Phospholipase D2-derived phosphatidic acid binds to and activates ribosomal p70 S6 kinase independently of mTOR. FASEB J 2007;21:1075-87. (Pubitemid 46495697)
32. Winter JN, Fox TE, Kester M, Jefferson LS, Kimball SR. Phosphatidic acid mediates activation of mTORC1 through the ERK signaling pathway. Am J Physiol Cell Physiol 2010;299: C335-44.
33. Carracedo A, Baselga J, Pandolfi PP. Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors. Cell Cycle 2008;7:3805-9.
34. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-88. (Pubitemid 44151605)
35. Makhlin I, Zhang J, Long CJ, Devarajan K, Zhou Y, Klein-Szanto AJ, et al. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int 2010 Nov 2. [Epub ahead of print].